RayKnowChina Research Map
Shortlist

RecruitingLymphomaPhase 1/Phase 2

Registered title, quoted from ClinicalTrials.gov

A Study of HDM2005 in Combination With Standard of Care in Patients With Diffuse Large B-Cell Lymphoma

An open trial on lymphoma, registered on ClinicalTrials.gov. The lead sponsor is not a hospital on this site; 19 hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 19

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Study siteFirst Affiliated Hospital of Nanchang University南昌大学第一附属医院NanchangHospital page
  2. Study siteFirst Affiliated Hospital of Xi'an Jiaotong University西安交通大学第一附属医院Xi'anHospital page
  3. Study siteFirst Affiliated Hospital of Zhengzhou University郑州大学第一附属医院ZhengzhouHospital page
  4. Study siteFirst Affiliated Hospital, Zhejiang University浙江大学医学院附属第一医院HangzhouHospital page
  5. Study siteFirst Hospital of Jilin University吉林大学第一医院ChangchunHospital page
  6. Study siteFujian Cancer Hospital福建省肿瘤医院FuzhouHospital page
  7. Study siteGuangxi Medical University Cancer Hospital广西医科大学附属肿瘤医院NanningHospital page
  8. Study siteHenan Cancer Hospital河南省肿瘤医院ZhengzhouHospital page
  9. Study siteHunan Cancer Hospital湖南省肿瘤医院ChangshaHospital page
  10. Study sitePeking University Cancer Hospital北京大学肿瘤医院BeijingHospital page
  11. Study siteSecond Affiliated Hospital of Soochow University苏州大学附属第二医院SuzhouHospital page
  12. Study siteShandong Cancer Hospital and Institute山东省肿瘤医院JinanHospital page
  13. Study siteShanxi Cancer Hospital山西省肿瘤医院TaiyuanHospital page
  14. Study siteShengjing Hospital of China Medical University中国医科大学附属盛京医院ShenyangHospital page
  15. Study siteSun Yat-sen University Cancer Center中山大学肿瘤防治中心GuangzhouHospital page
  16. Study siteTongji Hospital华中科技大学同济医学院附属同济医院WuhanHospital page
  17. Study siteUnion Hospital华中科技大学同济医学院附属协和医院WuhanHospital page
  18. Study siteWest China Hospital四川大学华西医院ChengduHospital page
  19. Study siteYunnan Cancer Hospital云南省肿瘤医院KunmingHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT07124936, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 6

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (6 points)Hide the checklist
  1. 18 years to 75 years; sex: all

    Registered eligibility fields

  2. Histologically confirmed diffuse large B-cell lymphoma (DLBCL).

    Inclusion criterion 4

  3. Cohort A: At least one (≥1) line of prior systemic therapy.

    Inclusion criterion 6

    Prior ROR1-targeted therapy.

    Exclusion criterion 11

  4. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

    Inclusion criterion 2

  5. At least one bi-dimensionally measurable (≥1.5 cm) nodal lesion, or one bi-dimensionally measurable (≥1 cm) extranodal lesion, as measured on computed tomography (CT) scan.

    Inclusion criterion 8

  6. Known additional malignancy that is progressing or has required active treatment within the past 3 years.

    Exclusion criterion 3

    Concurrent active HBV or HCV infection or known history of human immunodeficiency virus (HIV) infection.

    Exclusion criterion 10

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; blood tests: counts, liver and kidney function; pregnancy, breastfeeding and contraception.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07124936, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Male or female aged 18-75 years.
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
  • Life expectancy >12 weeks.
  • Histologically confirmed diffuse large B-cell lymphoma (DLBCL).

a. Cohort B: International Prognostic Index (IPI) score of 2-5.

  • Prior treatment:
  • Cohort A: At least one (≥1) line of prior systemic therapy.
  • Cohort B: Has received no prior treatment for DLBCL.
  • At least one bi-dimensionally measurable (≥1.5 cm) nodal lesion, or one bi-dimensionally measurable (≥1 cm) extranodal lesion, as measured on computed tomography (CT) scan.
  • Adequate organ system and hematologic function as defined in protocol.

Exclusion Criteria:

  • Known active central nervous system (CNS) lymphoma.
  • Prior of allogeneic hematopoietic stem cell transplantation and has acute or ongoing graft-versus-host disease (GVHD) of any grade.
  • Known additional malignancy that is progressing or has required active treatment within the past 3 years.
  • History of severe bleeding disorders.
  • History of interstitial lung disease or radiation pneumonitis.
  • Prior solid organ transplant.
  • Ongoing Grade >1 treatment-related adverse events.
  • Current or history of clinically significant cardiovascular and cerebrovascular diseases.
  • Active infection requiring systemic therapy.
  • Concurrent active HBV or HCV infection or known history of human immunodeficiency virus (HIV) infection.
  • Prior ROR1-targeted therapy.
  • Ongoing corticosteroid therapy.
  • Current active autoimmune disease or history of autoimmune disease requiring treatment.
  • History of drug anaphylaxis or severe food allergy.
  • Any history or current evidence of disease, treatment, or laboratory abnormality as determined by the investigator that may affect the study results, interfere with the subject's full participation in the study, or be contrary to the subject's best interests.

Quoted from ClinicalTrials.gov, NCT07124936, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT07124936, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT07124936